STOCKWATCH
·
Pharmaceutical Preparations
Quarterly ResultMay 13, 2026, 04:37 PM

Talphera Q1 Net Loss $2.56M, EPS $(0.04); Going Concern Doubt

AI Summary

Talphera reported a net loss from continuing operations of $2.56 million for the first quarter of 2026, an improvement from $2.67 million in the prior year, with basic and diluted loss per share at $(0.04). Despite raising $4.04 million through a private placement, the company's management expressed substantial doubt about its ability to continue as a going concern due to recurring operating losses and negative cash flows, indicating a need for additional capital within the next 12 months.

Key Highlights

  • Net loss from continuing operations was $(2.56) million for Q1 2026, compared to $(2.67) million in Q1 2025.
  • Basic and diluted loss per share was $(0.04) for Q1 2026, compared to $(0.10) in Q1 2025.
  • Revenue was $0 for Q1 2026, down from $27 thousand in Q1 2025.
  • Cash and cash equivalents totaled $3.82 million as of March 31, 2026, down from $5.89 million at December 31, 2025.
  • Net cash used in operating activities was $(3.40) million for Q1 2026.
  • The company raised $4.04 million in net proceeds from a private placement in Q1 2026.
  • Total current assets increased to $21.34 million as of March 31, 2026, from $20.90 million at December 31, 2025.
  • Warrant liability decreased to $1.15 million from $2.38 million.
TLPH
Pharmaceutical Preparations
TALPHERA, INC.

Price Impact